ClinicalTrials.gg
Active, not recruitingNCT06463171Updated Nov 18, 2026

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

A Phase 2 interventional study of Almonertinib in Lung Cancer Non-small Cell Stage IV, sponsored by Shanghai Pulmonary Hospital, Shanghai, China. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai Pulmonary Hospital, Shanghai, China · Phase 2, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now Active, not recruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung — 12 open to participants now, 18 under way, 7 of them phase 3. aumolertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
18th of 29
62 · median 150
Started
2024
with 3 others
Phase 2
14 of 29
6 open now
Primary completion
2027-08
later than 14 of 17 live
Registered
23rd of 29
by date
Lead sponsor
2 of 29
Shanghai Pulmonary Hospital, Shanghai, China

Among the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, this one is the 18th largest by enrollment, is one of 4 that started in 2024, is one of 14 in phase 2, reaches primary completion later than 14 of the 17 other live ones, and was the 23rd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

12 of the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About aumolertinib

aumolertinib: first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test in Locally Advanced or Metastatic Non-small Cell Lung Cancer patients with EGFR Mutations. The main question it aims to answer is:

Evaluation of the Efficacy and Safety of Aumolertinib in Combination with Lastet for the Treatment of EGFR-Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer in First-line Therapy.

Participants will be treated with a combination of Aumolertinib and Lastet.

03

Conditions studied

  • Lung Cancer Non-small Cell Stage IV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior to the implementation of any trial-related procedures, written must be obtained.
  • Age ≥18 years.
  • Patients with locally advanced (Stage III B/III C), , or recurrent (Stage IV) non-small cell lung cancer (NSCLC) confirmed histologically or cytologically, who are ineligible for surgical intervention and cannot undergo curative radiochemotherapy, as per the 8th edition TNM staging classification of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer.
  • Provide archived tumor tissue or tissue obtained from at screening for biomarker testing, including EGFR mutation status, etc.;
  • Presence of EGFR positive mutation;
  • Investigator confirmation of at least one according to 1.1 criteria.
  • Patients who have previously received platinum-containing chemotherapy/radiotherapy, neoadjuvant chemotherapy/radiotherapy, or radical radiochemotherapy for advanced disease, with disease progression occurring >6 months after the last treatment, may participate in this study;
  • Expected ≥3 months.
  • PS 0-1.
  • Adequate hematologic function, defined as an ≥1.5×10\^9/L, count ≥100×10\^9/L, ≥90g/L (without a history of blood transfusion in the past 7 days).
  • Adequate liver function, defined as total level ≤1.5 times the (ULN) and (AST) and alanine aminotransferase (ALT) levels ≤2.5 times ULN for all patients, or for patients with liver metastasis, AST and ALT levels ≤5 times ULN.
  • Adequate renal function, defined as serum creatinine ≤1.5 times ULN.
  • Adequate coagulation function, defined as (INR) or prothrombin time (PT) ≤1.5 times ULN; if a subject is on anticoagulant therapy, INR/PT should be within the therapeutic range set by the anticoagulant.
  • Women of must undergo a pregnancy test within 7 days prior to the start of treatment, with negative results; and reliable methods (such as intrauterine devices, oral contraceptives, and condoms) should be used during the trial and for 30 days after the end of the trial. Men of childbearing potential should use condoms for contraception during the trial and for 30 days after the end of the trial.
  • Willingness to comply with regular follow-up visits and adhere to trial requirements.

Exclusion criteria

Exclusion Criteria:

  • 1. Currently participating in an interventional clinical study treatment;
  • Have previously received anti-EGFR treatment;
  • Received traditional Chinese medicine with antitumor indications or immunomodulatory drugs (such as thymosin, interferon, interleukin, etc.) within 2 weeks before the first dose;
  • Have a history of allergic reactions to any of the study drug components.
  • Have active hemoptysis (more than half a teaspoon), active diverticulitis, abdominal abscess, gastrointestinal obstruction, and peritoneal ;
  • Have tumor compression of surrounding vital organs (such as the esophagus) with accompanying related symptoms, compression of the superior vena cava, or invasion of major mediastinal vessels, the heart, etc.;
  • Known to have . Patients judged by the investigator to be asymptomatic or have stable brain metastases may be enrolled;
  • Have active systemic infections, including tuberculosis (clinical diagnosis including medical history, physical examination, imaging findings, and TB testing according to local medical routines), (known to be HBV surface antigen (HBsAg) positive, with HBV DNA ≥1000cps/ml or the lower limit of the reference value), , or (HIV antibody positive);
  • Known to have mental illness or substance abuse that may affect compliance with trial requirements;
  • Recently treated with a full dose of oral or non-oral anticoagulants or thrombolytics. Prophylactic use of anticoagulants is allowed.
  • Have a medical history, disease, treatment, or laboratory abnormality that may interfere with the trial results or prevent the subject from participating in the study throughout, or the investigator considers participation in the study not to be in the best interest of the subject.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    combination therapy

    Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously. Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off.

    Drug: Almonertinib

Interventions

  • DrugAumolertinibStudies of AumolertinibAumolertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously. Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off.

    Also known as: Lastet

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    PFS is defined as the period from the start of treatment until the disease progresses or the patient dies from any cause, whichever came first, assessed up to 24 months

    Time frame: up to 24 months

Secondary outcomes

  1. Disease Control Rate

    Disease Control Rate (DCR) is to describe the proportion of patients who have achieved a response to treatment that includes not only complete and partial responses but also stable disease.

    Time frame: 24 months

  2. Duration of Response

    The Duration of Response (DoR) is a clinical measure to determine the length of time that a tumor continues to respond to treatment without the cancer worsening.

    Time frame: 24 months

  3. Objective Response Rate

    The Objective Response Rate (ORR) is a key metric used in oncology to assess the proportion of patients in a study or treatment group who achieve an objective response (CR or PR).

    Time frame: 24 months

  4. Overall Survival

    OS is measured from the date of the initiation of treatment to the date of death from any cause, whichever came first, assessed up to 24 months

    Time frame: up to 24 months

07

Study locations

2 sites
08

References and documents

Publications

  • Chen J, Wang L, Liu L, Zhao J, Wu Y, Yu X, Su C. Aumolertinib in combination with Lastet in the first-line treatment of EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (EVOLUTION): protocol for a single-arm, phase II clinical trial. BMJ Open. 2025 Apr 29;15(4):e097576. doi: 10.1136/bmjopen-2024-097576. PubMed 40306921 ↗

Individual participant data

Plan to share: No — In clinical trials, it is essential to strictly protect the privacy of patients' personal information. Data sharing may inappropriately increase the risk of privacy breaches, especially when data anonymization is not handled properly. Additionally, researchers or sponsors, based on their considerations of data ownership and intellectual property rights, have the authority to decide whether and how to share the data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Aug 2027, 37 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 37 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Jun 2024 → Jul 2024, primary completion Jun 2026 → Aug 2027 and completion Jun 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 17, 2024
StartActual
Jul 1, 2024was Jun 2024
Primary completionEst.
Aug 1, 2027was Jun 2026
CompletionEst.
Aug 1, 2027was Jun 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Nov 18, 2026
Start date
Jun 2024→Jul 1, 2024 (actual)
Nov 18, 2026
Primary completion
Jun 2026→Aug 1, 2027
Nov 18, 2026
Study completion
Jun 2026→Aug 1, 2027
Nov 18, 2026
Enrollment
60 (estimated)→62 (actual)
Nov 18, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40306921 ↗
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40306921 ↗
    Start date Jun 2024→Jul 1, 2024 (now actual)
    Primary completion Jun 2026→Aug 1, 2027
    Study completion Jun 2026→Aug 1, 2027
    Enrollment 60 (estimated)→62 (actual)
    + 3 other changes: verification date, criteria formatting and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06463171
Responsible party
Chunxia Su (Director of the Clinical Research Center, Shanghai Pulmonary Hospital, Shanghai, China) — Principal investigator
First posted
Jun 17, 2024
Start date
Jul 1, 2024
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Chunxia Su
principal investigator · Shanghai Pulmonary Hospital, Shanghai, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aumolertinib

Start the discussion